IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
Trial details
- Registry ID
- NCT05987332
- Phase
- Phase 2, Phase 3
The FDA approved Dacarbazine (DIC) on 27 May 1975.
Drug identity checked against registry records
Also recorded as DIC; DTIC; DTIC-Dome; Imidazole Carboxamide
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaNCT05987332 | IDEAYA Biosciences | Phase 2, Phase 3 | Active not recruiting | 2027-01-15Estimated |
| A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)NCT06346067 | ERAS | Phase 3 | Active not recruiting | 2028-04Estimated |
| Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal MelanomaNCT03070392 | Immunocore Ltd | Phase 2 | Completed | 2020-10-13Actual |
| A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)NCT05269355 | PTC Therapeutics | Phase 2, Phase 3 | Terminated | 2024-06-17Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 1975-05-27Day | Dacarbazine | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA017575", "applicant_as_listed_by_fda": "BAYER HLTHCARE", "brand_names": ["DTIC-DOME"], "active_ingredients": ["DACARBAZINE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19750527", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |